Results 141 to 150 of about 34,445,663 (284)

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association. [PDF]

JACC Case Rep
Yeo YH, Dixon SR.
europepmc   +1 more source

Astragaloside IV Restores Autophagy and Inhibits Apoptosis for Podocyte Protection in Diabetic Nephropathy by Inhibiting Notch1 Signaling via SIRT6‐Mediated Deacetylation

Phytotherapy Research, EarlyView.
AS‐IV binds to SIRT6 and promotes H3K9 deacetylation at the Notch1 promoter, inhibiting gene transcription (Created with BioGDP.com). ABSTRACT Astragaloside IV (AS‐IV) has demonstrated efficacy in ameliorating proteinuria and attenuating renal tubular damage in preclinical diabetic nephropathy (DN) models.
Qiyu Yue, Chen Yong, Xinran Wang, Yang Shu, Min Yao, Yongfei Yu, Yubai Xue, Rong Deng, Tianlu Chu, Weiwei Tao, Min Zhao, Enchao Zhou   +11 more
wiley   +1 more source

Mogroside V Promotes Brown Adipose Thermogenesis via FTO‐m6A‐LETMD1‐UCP1 Pathway to Combat Obesity

Phytotherapy Research, EarlyView.
Mogroside V (MV) alleviates high‐fat diet‐induced obesity and metabolic dysfunction. Mechanistically, MV suppresses FTO expression, thereby increasing m6A modification of Letmd1 mRNA and enhancing its YTHDC2‐dependent stabilization. Theincreased LETMD1 expression is associated with elevated PGC1α and UCP1 levels, contributing to brown adipocyte ...
Yuan‐hai Sun, Ling‐huan Li, Ya‐qian Feng, Teng‐jiao Zhao, Min‐you Qi, Han‐bing Li   +5 more
wiley   +1 more source

History of glucagon-like peptide-1 receptor agonists

Pharmacological Research
Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler   +2 more
openaire   +2 more sources

Gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy

VIEW, EarlyView.
This graphical abstract illustrates how gut dysbiosis drives diabetic retinopathy through the gut‐retina axis, a process unfolding in three interconnected stages. First, in the gut, a decrease in beneficial bacteria and an increase in pro‐inflammatory taxa compromise the intestinal barrier, causing a “leaky gut” that allows LPS to translocate into the ...
Junyan Hu, Jingxiang Zhong
wiley   +1 more source

Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity. [PDF]

J Neurol Sci
Chen H, Lakhani DA, Yaddanapudi SS, Latifikhereshky S, Rai P, Kakadiya J, Malhotra A, Colasurdo M, Gandhi D.   +8 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis

Cureus
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) play a pivotal role in managing type 2 diabetes mellitus (T2DM), obesity, and other conditions, with proven benefits including, but not limited to, weight loss, glycemic control, and cardiovascular protection. However, their implications for arthritis are still debatable. GLP-1RAs may reduce systemic
openaire   +3 more sources

Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis

VIEW, EarlyView.
In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian, Keke Zhang, Wenwen He, Yan Ke, Yi Lu, Xiangjia Zhu   +5 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Pregnancy: Periconception Exposure and Perinatal Outcomes

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective An increasing number of women of childbearing age worldwide are using glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and are advised to use effective contraception during treatment. Nevertheless, maternity services are encountering increasing numbers of women exposed to GLP‐1 RAs shortly before conception or during pregnancy ...
Katherine G. Y. Lau, Anisha Chopra, Edward Mullins, Rochan Agha‐Jaffar, Tricia Tan, Lynne Sykes, Christina K. H. Yu   +6 more
wiley   +1 more source